Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04767009 | SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors | unknown | Phase 2 | 59 | Fudan UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT05623956 | Proteomics in Small Cell Lung Cancer(SCLC-OMICS) | unknown | — | 50 | Aalborg University HospitalOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT01753414 | Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC(POSTILV) | unknown | Phase 2 | 44 | Radiation Therapy Oncology GroupNETWORK | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05922345 | Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. | unknown | Phase 3 | 518 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06403111 | FMT+Immunotherapy+Chemotherapy As First-line Treatment for Driver-gene Negative Advanced NSCLC | unknown | Phase 2 | 62 | Changzhou No.2 People's HospitalOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06733311 | A Study Developing a Non-invasive Urine-based Proteomic Model for Early Lung Cancer Detection.(UPD-LC) | unknown | — | 480 | Beijing Chao Yang HospitalOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06697990 | Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients | unknown | Phase 2 | 12 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06623786 | Cancer Patient Remote Monitoring for Timely Communication Study(CONNECT) | unknown | — | 100 | Asklepios proresearchINDUSTRY | 0 | Oct 2, 2024 | clinicaltrials |
| NCT06406166 | Lifei Xiaoji Wan in Treatment of Advanced NSCLC | unknown | N/A | 100 | Henan University of Traditional Chinese MedicineOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT06215885 | Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid Nodules | unknown | — | 220 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT06586697 | First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06590194 | PH009-1 in Patients With EGFR Mutation Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | unknown | Phase 1 / Phase 2 | 96 | Suzhou Puhe Pharmaceutical Technology Co., LTDINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06481566 | Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial | unknown | N/A | 30 | Chongqing University Cancer HospitalOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | unknown | Phase 2 | 30 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | unknown | Phase 3 | 202 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT06564870 | Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer(DURVABREIZH) | unknown | — | 200 | University Hospital, BrestOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06558903 | Searching for Predictive Biomarkers of Efficacy in Small Cell Lung Cancer Patients Treated With Chemotherapy-immunotherapy Combination Using Imaging Mass Cytometry (HYPE)(HYPE) | unknown | — | 20 | University Hospital, BrestOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT05222087 | PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot Study(PRIME_LUNG) | unknown | Phase 1 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT05805319 | Dietary Intervention for NSCLC Patients Treated With ICI | unknown | N/A | 80 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT05748093 | Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat(OSIBOOST 2) | unknown | Phase 4 | 60 | Maastricht University Medical CenterOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06479473 | Radiotherapy to All Residual Lesions After Chemoimmunotherapy | unknown | Phase 1 / Phase 2 | 150 | Anhui Provincial HospitalOTHER_GOV | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03866499 | A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients | unknown | Phase 3 | 369 | Beta Pharma ShanghaiINDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06496360 | Prediction of Mediastinal Station IV Lymph Node Metastasis in Non-small Cell Lung Cancer | unknown | — | 150 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06234579 | Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)(GALILEO) | unknown | — | 108 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06530797 | A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer | unknown | — | 2,000 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 0 | Jul 31, 2024 | clinicaltrials |
| NCT05801406 | From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.(Vortex_US) | unknown | — | 5 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT06511661 | Prognostic Significance of the Uncertain Resection in NSCLC | unknown | — | 3,783 | Sun Yat-sen UniversityOTHER | 1 | Jul 25, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT05987345 | Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer | unknown | N/A | 10 | Energenx Medical LTD.INDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06331455 | Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection(SUPER) | unknown | Phase 2 | 12 | Marc de PerrotOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT05837429 | Low Volume High Intensity Interval Training in Operated Lung Cancer Patients | unknown | N/A | 40 | Hacettepe UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT04712877 | Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | unknown | — | 1,000 | Lung Cancer Mutation ConsortiumNETWORK | 1 | Jul 17, 2024 | clinicaltrials |
| NCT05183243 | GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results | unknown | Phase 1 | 68 | Suzhou Genhouse Bio Co., Ltd.OTHER | 1 | Jul 16, 2024 | clinicaltrials |
| NCT05271292 | Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.(SCLC) | unknown | Phase 1 / Phase 2 | 36 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT06503042 | A Study to Prospectively Validate Blood Markers Associated With Differences in Efficacy of Neoadjuvant Therapy for NSCLC | unknown | — | 100 | Tang-Du HospitalOTHER | 0 | Jul 16, 2024 | clinicaltrials |
| NCT01456429 | Assessment of Invasive Mediastinal Staging in cN1 Lung Cancer.(ASTER2) | unknown | N/A | 100 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Jul 15, 2024 | clinicaltrials |
| NCT06362980 | A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations(EGFR) | unknown | Phase 1 | 20 | National Cancer Center, ChinaOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05244213 | Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC(NEOTIDE) | unknown | Phase 2 | 35 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04562337 | SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC | unknown | Phase 2 | 67 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06483919 | The Predictive Value of Proteome Profiling for Brain Metastasis in Limited-Stage Small-Cell Lung Cancer | unknown | — | 228 | Jinming YuOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06485557 | A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC | unknown | Phase 3 | 90 | Tang-Du HospitalOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT04807114 | A Single-cell Approach to Identify Biomarkers of Efficacy and Toxicity for ICI in NSCLC | unknown | — | 70 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06479005 | ETERNALS: Remote Monitoring in Lung Cancer Patients(ETERNALS) | unknown | N/A | 50 | Ziekenhuis Oost-LimburgOTHER | 1 | Jul 1, 2024 | clinicaltrials |
| NCT06118229 | A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients | unknown | — | 300 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06479759 | LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer(ACCLAIM) | unknown | Phase 2 | 50 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jun 28, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2025source: clinicaltrials